GCC Nurse COVID-19 Guide

🦠SARS-CoV-2 Mechanism of Infection

ACE2 Receptor Binding

SARS-CoV-2 enters host cells via the spike (S) protein binding to Angiotensin-Converting Enzyme 2 (ACE2) receptors. ACE2 is highly expressed in the lungs (type II pneumocytes), heart, kidneys, intestines, and vascular endothelium — explaining multi-organ tropism.

The spike protein is primed by TMPRSS2 (transmembrane serine protease 2), facilitating membrane fusion and viral entry. This step is a key therapeutic target.

Viral Replication Cycle

After cell entry, the virus releases its RNA genome. RNA-dependent RNA polymerase replicates viral RNA. Structural proteins assemble in the endoplasmic reticulum. New virions bud and spread to neighbouring cells and via respiratory droplets/aerosols.

Key nursing insight: The high ACE2 density in lungs and endothelium explains why COVID-19 causes both respiratory failure and systemic vascular complications.

Variants: Comparative Severity

Variant	Period	Relative Severity	Immune Evasion	Key Feature
Alpha B.1.1.7	Late 2020	Higher than wild-type (~50% more hospitalisation)	Moderate	N501Y mutation — increased ACE2 affinity
Delta B.1.617.2	2021	Highest severity; highest ICU rates	Moderate	More fusogenic, rapid viral replication, severe pneumonia
Omicron B.1.1.529	Late 2021–present	Lower severity per infection (more upper respiratory)	High	~30+ spike mutations; more transmissible; less pneumonia; BA.5/XBB subvariants

📊Clinical Spectrum & WHO Severity Classification

WHO Category	Clinical Features	SpO2	Setting
Mild	Symptoms without breathlessness (fever, cough, sore throat, myalgia, anosmia). No pneumonia signs.	≥95% on room air	Home isolation
Moderate	Clinical or radiological pneumonia. No severe hypoxia. Tachypnoea may be present.	90–94% on room air	Hospital ward
Severe	SpO2 <90%, RR ≥30/min, severe respiratory distress, or sepsis criteria	<90% on room air	HDU / ICU step-down
Critical	ARDS, septic shock, multi-organ failure requiring ICU-level interventions	Requires MV/NIV	ICU

Clinical progression can be rapid — reassess every 4–8 hours in hospitalised patients. SpO2 trending downward even within normal range warrants escalation.

🔥Cytokine Storm Pathophysiology

In severe COVID-19, dysregulated immune activation causes massive cytokine release (IL-6, IL-1β, TNF-α, IFN-γ). This "cytokine storm" leads to:

Diffuse alveolar damage and ARDS
Capillary leak and oedema
Endothelial activation and thrombosis
Myocardial depression and shock
Acute kidney injury

Biomarkers of cytokine storm: elevated CRP, ferritin, LDH, IL-6, lymphopaenia, elevated D-dimer. Daily monitoring is essential in severe cases.

Endothelialitis

Direct viral infection of endothelial cells (via ACE2) causes endothelialitis — widespread endothelial dysfunction contributing to microvascular thrombosis, ischaemia, and organ injury across heart, lungs, kidneys, and brain.

Myocarditis

COVID-19 myocarditis occurs in ~1–3% of hospitalised cases (higher with severe disease). Mechanism: direct viral myocyte injury + immune-mediated damage. Troponin elevation is the key marker. Monitor for new arrhythmias, chest pain, and haemodynamic instability.

🩸COVID-Associated Coagulopathy (CAC)

Mechanism

Hypercoagulability in COVID-19 results from endothelial injury, platelet activation, and inflammatory cytokine-driven coagulation cascade activation. This is distinct from classic DIC.

Laboratory Findings

Markedly elevated D-dimer (strongest predictor of severity)
Elevated fibrinogen (acute phase reactant)
Mildly prolonged PT/APTT
Thrombocytopaenia (usually mild)

Clinical Complications

PE (Pulmonary Embolism): most common thromboembolic event in COVID ICU patients
DVT: often bilateral; even with prophylaxis
Stroke: large vessel occlusion in young patients
Microvascular thrombosis: contributes to ARDS, AKI, organ failure

All hospitalised COVID patients require VTE risk assessment and prophylactic anticoagulation unless contraindicated.

💨Oxygen Therapy — WHO Targets & HFNC

SpO2 Targets

General hospitalised COVID: SpO2 ≥94% (avoid unnecessary high-flow O2)
Mechanically ventilated: SpO2 90–96% (avoid hyperoxia)
COPD/risk of hypercapnia: SpO2 88–92%
Pregnant women: SpO2 ≥95%

Oxygen Delivery Devices

Nasal cannula: 1–6 L/min (FiO2 ~24–44%)
Simple mask: 6–10 L/min (FiO2 ~35–50%)
NRM (Non-rebreather mask): 10–15 L/min (FiO2 ~60–80%)
HFNC: up to 60 L/min, FiO2 up to 1.0

High-Flow Nasal Cannula (HFNC)

HFNC delivers heated, humidified oxygen at high flows, reducing dead space and providing low-level PEEP. Preferred step-up from conventional O2 before intubation in COVID pneumonia.

ROX Index = (SpO2/FiO2) / RR

        ROX ≥4.88 at 12 hours → LOW risk of intubation failure

        ROX <3.85 → HIGH risk → consider escalation to intubation

        ROX 3.85–4.88 → intermediate — close monitoring required

With HFNC: place surgical mask over the nasal cannula to reduce aerosol dispersal. Treat as AGP — N95/FFP2 required.

🔄Awake Proning

Awake proning (prone positioning in non-intubated patients) recruits posterior lung segments that are preferentially affected in COVID-19 pneumonia, improving V/Q matching and oxygenation.

Protocol

30 minutes × 4 sessions per day (minimum)
Positions: fully prone → right lateral → sitting upright → left lateral
Rotate every 30–120 minutes as tolerated
Supported with pillows under chest/pelvis

Nursing Considerations

Ensure IV lines/monitoring secured before repositioning
Monitor SpO2 continuously during proning
Document position times and SpO2 response
Contraindications: haemodynamic instability, recent abdominal surgery, facial injuries, inability to self-reposition, uncooperative patient

Studies show awake proning can improve SpO2 by 5–10% and may reduce need for intubation when combined with HFNC.

🫁Mechanical Ventilation in COVID ARDS

Lung-Protective Ventilation

Tidal Volume (VT): 6 ml/kg Ideal Body Weight (IBW)
Plateau pressure (Pplat): ≤30 cmH2O
Driving pressure: ≤15 cmH2O
PEEP: Titrated to oxygenation (higher PEEP for lower P/F ratio)
RR: 14–35/min to target pH ≥7.25
Permissive hypercapnia: pH ≥7.25 acceptable

Prone Ventilation

For severe ARDS (P/F ratio <150): prone ventilation ≥16 hours per day. Improves dorsal lung recruitment, reduces mortality in ARDS (PROSEVA trial — 28-day mortality reduced by ~16%).

Nursing Role in Proning

Minimum 5-person team (1 leads, 4 reposition)
Secure ETT, lines, and catheters before turn
Pressure injury prevention: facial padding, hourly repositioning of head
Monitor haemodynamics continuously during turn

Eye care: lubricating drops every 2 hours, keep eyes closed and padded to prevent corneal injury during prone ventilation.

💉Anticoagulation in COVID-19

Indication	Regimen	Target
All hospitalised COVID (prophylaxis)	LMWH (enoxaparin) prophylactic dose: 40mg SC daily (30mg if CrCl <30)	VTE prevention
Moderate-severe with elevated D-dimer (>2× ULN)	Therapeutic LMWH: 1mg/kg SC BD (consider per ATTACC/ACTIV-4A trial)	Macro/microthrombosis prevention
Confirmed PE/DVT	Full therapeutic anticoagulation (LMWH or UFH per haematology)	Treatment of VTE
Post-discharge	Consider extended VTE prophylaxis ×2–4 weeks in high-risk patients	Extended prevention

Therapeutic anticoagulation is NOT recommended in critically ill mechanically ventilated COVID patients (REMAP-CAP/ATTACC: no benefit, possible harm in ICU). Prophylactic dosing remains standard for ICU patients.

💊Corticosteroids — RECOVERY Trial Evidence

Dexamethasone 6mg once daily × 10 days (or until discharge) — indicated for all patients requiring supplemental oxygen or mechanical ventilation.

RECOVERY Trial Key Findings

28-day mortality reduced by 35% in ventilated patients
28-day mortality reduced by 20% in O2-requiring patients
No benefit (possible harm) in patients NOT requiring O2
IV or oral route equally effective

Nursing Monitoring on Dexamethasone

Blood glucose: hyperglycaemia common — 4-hourly CBG monitoring
Fluid retention and hypertension
Infection risk: monitor for secondary infections (bacterial/fungal)
Mood changes / agitation (steroid psychosis — rare)
GI protection: PPI co-prescription often needed

Alternative: methylprednisolone 0.5–1 mg/kg/day if dexamethasone unavailable. Hydrocortisone 200mg/day for septic shock component.

COVID-19 Severity Classifier

Enter clinical parameters to determine WHO severity category and management setting.

SpO2 (%)

Respiratory Rate (/min)

Supplemental O2 Needed?

Consciousness/GCS

ROX Index Calculator (HFNC Failure Risk)

ROX Index = (SpO2 / FiO2) / Respiratory Rate. Assess at 2h, 6h, and 12h after HFNC initiation.

SpO2 (%)

FiO2 (decimal: 0.21–1.0)

Respiratory Rate (/min)

Time after HFNC start

💊Antiviral Agents

Remdesivir (IV)

Mechanism: RNA-dependent RNA polymerase inhibitor

Indication: High-risk moderate disease; within 7 days of symptom onset; hospitalised patients requiring supplemental O2

Dose: 200mg loading IV then 100mg OD × 4 days (total 5 days)

Nursing: Monitor liver enzymes (ALT/AST), bradycardia, and infusion reactions. Avoid if eGFR <30 (IV formulation contains sulfobutylether β-cyclodextrin).

Molnupiravir (Oral)

Mechanism: Mutagenic nucleoside analogue — introduces errors into viral RNA replication

Indication: Mild-moderate COVID in high-risk non-hospitalised adults; within 5 days symptoms

Dose: 800mg BD × 5 days

Contraindication: Pregnancy (teratogenic risk), paediatrics. Not for use in severely ill.

Nirmatrelvir/Ritonavir (Paxlovid — Oral)

Mechanism: Nirmatrelvir inhibits SARS-CoV-2 3CL protease; ritonavir boosts levels via CYP3A4 inhibition

Indication: High-risk mild-moderate COVID; within 5 days symptoms. Most effective antiviral in outpatient setting.

Dose: Nirmatrelvir 300mg + ritonavir 100mg BD × 5 days

Drug interactions: ritonavir is a potent CYP3A4 inhibitor. Interacts with statins (myopathy), immunosuppressants (tacrolimus/cyclosporin — toxic levels), anticoagulants, antiepileptics, antiarrhythmics. ALWAYS check drug interactions before dispensing.

Monoclonal Antibodies

Neutralising antibodies against spike protein. Efficacy is highly variant-dependent — most were rendered ineffective by Omicron and subvariants. Examples: sotrovimab (retained partial Omicron activity), bebtelovimab (BA.5 activity). Clinical utility limited in current landscape — check current WHO/MOH guidance for approved agents.

🧬Immunomodulators

Tocilizumab (IL-6 Receptor Inhibitor)

Indication: Severe/critical COVID-19 with elevated inflammatory markers + already on corticosteroids

Dose: 8mg/kg IV (max 800mg) — single dose; second dose possible at 24h

Evidence: RECOVERY/REMAP-CAP trials — significant mortality reduction in severe COVID

Nursing: Infusion reactions (fever, chills), increased infection risk (especially reactivation of TB/hepatitis B), LFT elevation

Baricitinib (JAK Inhibitor)

Indication: Alternative to tocilizumab in severe/critical COVID; also used when IL-6 inhibitors unavailable

Dose: 4mg OD orally × up to 14 days

Nursing: Renal dose adjustment required. Monitor for DVT/PE, elevated lipids, infection risk.

Dexamethasone

Only steroid with mortality benefit in COVID-19. 6mg OD × 10 days for O2-requiring patients (RECOVERY trial). Do NOT give to patients not requiring O2.

Convalescent Plasma

WHO and most guidelines no longer recommend convalescent plasma for treatment of COVID-19 hospitalised patients — evidence showed no mortality benefit (RECOVERY trial). May have limited role in immunocompromised patients.

Antibiotic Stewardship

COVID-19 is a viral illness. Secondary bacterial co-infection is uncommon in the first 48–72 hours (<5% of admitted patients). Avoid empirical antibiotics without clinical/microbiological evidence. Reserve for: worsening fever after day 3, purulent secretions, rising WBC/procalcitonin, radiological consolidation, positive cultures.

Inappropriate antibiotic prescribing in COVID surges significantly contributed to antimicrobial resistance globally. The nurse's role: challenge unjustified prescriptions and document reasoning.

📋Treatment Algorithm Summary

Severity	Antiviral	Steroid	Immunomodulator	Anticoagulation
Mild (no O2)	Paxlovid/Molnupiravir if high-risk	NOT indicated	NOT indicated	Prophylactic if hospitalised
Moderate (O2)	Remdesivir IV 5 days	Dexamethasone 6mg	Consider if deteriorating	Prophylactic LMWH
Severe (high O2)	Remdesivir	Dexamethasone 6mg	Tocilizumab + Dex	Therapeutic LMWH (if D-dimer elevated)
Critical (ICU/MV)	Remdesivir (if <7d from onset)	Dexamethasone 6mg	Tocilizumab/Baricitinib	Prophylactic LMWH (NOT therapeutic)

🛡️Aerosol-Generating Procedures (AGPs) — PPE Requirements

ALL AGPs require: N95/FFP2/FFP3 respirator + eye protection (goggles or face shield) + fluid-resistant gown + gloves

Procedures Classified as AGPs

Tracheal intubation and extubation
Bag-mask ventilation (manual ventilation)
Open airway suctioning
Bronchoscopy
Tracheostomy insertion/care
CPAP/BiPAP initiation
High-Flow Nasal Cannula (HFNC) — debated; treat as AGP
Nebuliser administration (switch to MDI spacer when possible)
Sputum induction / nasopharyngeal sampling
CPR (chest compressions + airway management)

HFNC — Special Considerations

HFNC aerosol risk is debated. Current guidance: treat as AGP. Mitigating measures:

Place surgical mask over HFNC prongs during patient use
Use in negative pressure room if available
Minimise staff entering room during HFNC
N95/FFP2 for all staff entering room

Research (e.g. HFNO studies) shows aerosol dispersal with HFNC is similar to or less than NRM — but institutional policy often defaults to AGP classification for safety.

🏥PPE Standards by Setting

Setting	Minimum PPE	Additional for AGPs
COVID Ward (non-AGP)	Surgical mask + apron + gloves + eye protection (if splash risk)	+ N95/FFP2 + gown
COVID ICU (routine care)	Surgical mask + fluid-resistant gown + gloves + eye protection	+ N95/FFP2 during AGPs
COVID ICU (AGP)	N95/FFP2 + face shield + fluid-resistant gown + gloves	Consider FFP3 for intubation
COVID-19 isolation room	Per above based on activity	Maintain negative pressure
Emergency/Resuscitation	N95/FFP2 + face shield + gown + gloves — ALWAYS	Full AGP PPE for all

🌬️Negative Pressure Room Requirements

Confirmed or suspected COVID-19 patients with AGP risk require negative pressure isolation rooms:

≥12 Air Changes per Hour (ACH) — WHO recommendation for airborne precautions
Negative pressure differential: ≥2.5 Pa negative relative to corridor
Air exhausted directly outside (not recirculated without HEPA)
Self-closing doors; anteroom/vestibule preferred for PPE donning/doffing
Pressure monitoring: visual indicator (tissue/smoke pen) or digital manometer

When Negative Pressure is Unavailable

Use single-occupancy room with door closed
Portable HEPA air purifiers as adjunct
Minimise staff/visitors in room
Open windows if safe and feasible (natural ventilation)
Cohort COVID patients in dedicated zones

GCC context: many older hospital buildings in the region may not have purpose-built negative pressure rooms — portable HEPA filtration and strict cohorting are key mitigating strategies.

🧤PPE Doffing Sequence — Highest Risk Step

Doffing (removal) of PPE is the highest risk step for self-contamination. The outside surfaces of gloves and gown are contaminated.

Recommended Doffing Sequence (WHO/CDC)

Perform hand hygiene
Remove gloves (peel off — touch inside only)
Perform hand hygiene
Remove gown (roll down away from body)
Perform hand hygiene
Remove eye protection (handle by back/strap only)
Perform hand hygiene
Remove N95/respirator (handle by straps only — touch mask minimally)
Perform hand hygiene

Key Principles

Always perform hand hygiene between each step
Buddy system: a trained observer watches for errors
Slow, deliberate movements — avoid touching face
Doff in dedicated doffing area (outside patient room)
N95 mask removed LAST (face protection retained longest)
Dispose PPE in clinical waste bin immediately

Face touching during doffing is the primary route of self-contamination. Studies show healthcare workers frequently touch their face without awareness — buddy checking is essential.

🔬Variant Transmission Characteristics & HCW Vaccination in GCC

Omicron — Transmission Changes

Significantly more transmissible than Delta (R0 estimated 10–18)
Preferentially replicates in upper respiratory tract (nasopharynx/trachea) rather than lower respiratory
Shorter incubation period (~3 days vs 4–5 for Delta)
Higher risk of HCW infection despite full vaccination (immune evasion)
Implications: rapid staff depletion during surges; enhanced PPE adherence more critical than ever

GCC HCW Vaccination Requirements

UAE: COVID vaccination mandated for all healthcare workers; DHA/DOH licensing requires vaccination documentation
Saudi Arabia: SCFHS (Saudi Commission) mandated vaccination for HCW renewal; Tawakkalna app verification
Qatar: MOPH mandated HCW vaccination; QCHP licensing conditional
Kuwait/Bahrain/Oman: Strong institutional requirements across MOH facilities
Booster doses recommended for HCW due to waning immunity and high-exposure risk

🔁Long COVID — Definition & Prevalence

WHO Definition

Post-COVID condition (Long COVID) is defined as symptoms occurring in individuals with history of probable or confirmed SARS-CoV-2 infection, usually within 3 months of onset, lasting at least 2 months, and not explained by alternative diagnosis.

UK NICE definition: symptoms persisting >12 weeks after acute COVID onset, not explained by alternative cause.

Long COVID can occur after any severity of acute illness — including asymptomatic cases. It is NOT limited to those hospitalised.

Prevalence Estimates

After hospitalisation: 10–20% of patients have persistent symptoms at 6 months
After mild/moderate COVID: 1–3% develop significant long COVID symptoms
Higher risk: Female sex, obesity, older age, multiple acute symptoms, not vaccinated
Vaccination effect: 2 doses of mRNA vaccine reduce long COVID risk by ~50% compared to unvaccinated
Global burden: WHO estimates ~10–20 million people globally with disabling long COVID

📝Symptoms & Mechanisms

Common Symptoms (in frequency order)

Fatigue — most prevalent (50–70%); post-exertional malaise
Dyspnoea — exertional breathlessness; often without hypoxia
Brain fog / Cognitive impairment — memory problems, difficulty concentrating
Palpitations — often POTS-related (see below)
Joint and muscle pain — myalgia, arthralgia
Sleep disturbance — insomnia, non-restorative sleep
Persistent cough, chest pain, headache
Anosmia/parosmia — altered smell
Anxiety and depression — significant psychological burden

Proposed Mechanisms

Viral persistence: ongoing low-level replication in reservoirs (gut, lymph nodes)
Autoimmunity: molecular mimicry triggering autoantibodies against host tissues
Microbiome disruption: gut dysbiosis correlates with long COVID severity
Mitochondrial dysfunction: impaired energy metabolism in muscle/neurons
Small fibre neuropathy: confirmed on skin biopsy in some patients; explains pain/autonomic symptoms
Endothelial microclots: fibrin-amyloid microclots found in long COVID blood samples

❤️Post-COVID Cardiac Complications

Myocarditis

Post-COVID myocarditis may present weeks to months after acute illness. Incidence higher in males and those with severe acute illness, but also reported in mild cases.

Nursing Monitoring

Troponin I/T serial monitoring in symptomatic patients
12-lead ECG for palpitations/chest pain
Echocardiography referral for new wall motion abnormalities
Restrict strenuous exercise until cardiac clearance
Cardiac MRI is diagnostic gold standard

POTS — Postural Orthostatic Tachycardia Syndrome

POTS is a dysautonomia syndrome increasingly recognised in long COVID. Hallmark: heart rate increase ≥30 bpm (adults) upon standing, with symptoms of lightheadedness, palpitations, fatigue.

Nurse Recognition

Active stand test: HR and BP supine vs. 1, 3, 5 min standing
HR rise ≥30 bpm without significant BP drop = POTS
Symptoms: pre-syncope on standing, fatigue worse upright
Management: increase salt/fluid intake, compression stockings, graded exercise, beta-blockers (ivabradine)

POTS is frequently missed as a cause of long COVID fatigue and palpitations. Screen with simple active stand test in all symptomatic long COVID patients.

🏃Rehabilitation Approach

Graded Activity — KEY PRINCIPLE: PACING

Unlike many other conditions, aggressive exercise rehabilitation is CONTRAINDICATED in long COVID with post-exertional malaise (PEM). Overexertion causes symptom relapse ("crashes").

Pacing: Activity within symptom-free envelope; stop before fatigue onset
Energy conservation: Prioritise activities; rest regularly
Graded increase: Only increase activity when 2–3 days at current level without PEM
Physiotherapy: Breathing retraining, dysfunctional breathing correction, posture

Multidisciplinary Rehabilitation

Occupational Therapy: ADL assessment, cognitive fatigue management, return to work planning
Psychology/Psychiatry: CBT for health anxiety, depression treatment, sleep intervention
Dietetics: Nutritional support, gut microbiome optimisation
Neurology: For cognitive symptoms, small fibre neuropathy, POTS
Cardiology/Respiratory: For cardiac and pulmonary sequelae

GCC Long COVID Clinics

Dedicated long COVID clinics established in: Dubai (Cleveland Clinic, Rashid Hospital), Abu Dhabi (SEHA), Riyadh (KFMC, KFSH&RC), Doha (HMC), Kuwait City (MOH specialist centres).

Vaccine	Type	GCC Countries	Efficacy (Original/Delta)	Notes
BNT162b2 (Pfizer)	mRNA	All 6 GCC states	~95% / ~88% (2 doses)	Gold standard; required booster at 6 months
mRNA-1273 (Moderna)	mRNA	UAE, Qatar, Saudi	~94% / ~86%	Higher dose; slightly longer durability
AstraZeneca (ChAdOx1)	Viral vector	Saudi, Kuwait, Oman, Bahrain	~70–79% / ~67%	Rare VITT (vaccine-induced thrombosis); removed <30y
Sinopharm (BBIBP-CorV)	Inactivated	UAE, Bahrain	~79% symptomatic; lower vs Delta	Required booster with mRNA for adequate protection
Sputnik V	Viral vector	UAE, Kuwait, Bahrain	~92% (early data)	Limited peer-reviewed GCC data
Janssen (Ad26)	Viral vector	Kuwait, Qatar	~66–72% (single dose)	Single dose; rare VITT; heterologous boost recommended

🦠SARS-CoV-2 Mechanism of Infection

ACE2 Receptor Binding

Viral Replication Cycle

Variants: Comparative Severity

📊Clinical Spectrum & WHO Severity Classification

🔥Cytokine Storm Pathophysiology

Endothelialitis

Myocarditis

🩸COVID-Associated Coagulopathy (CAC)

Mechanism

Laboratory Findings

Clinical Complications

💨Oxygen Therapy — WHO Targets & HFNC

SpO2 Targets

Oxygen Delivery Devices

High-Flow Nasal Cannula (HFNC)

🔄Awake Proning

Protocol

Nursing Considerations

🫁Mechanical Ventilation in COVID ARDS

Lung-Protective Ventilation

Prone Ventilation

Nursing Role in Proning

💉Anticoagulation in COVID-19

💊Corticosteroids — RECOVERY Trial Evidence

RECOVERY Trial Key Findings

Nursing Monitoring on Dexamethasone

COVID-19 Severity Classifier

ROX Index Calculator (HFNC Failure Risk)

💊Antiviral Agents

Remdesivir (IV)

Molnupiravir (Oral)

Nirmatrelvir/Ritonavir (Paxlovid — Oral)

Monoclonal Antibodies

🧬Immunomodulators

Tocilizumab (IL-6 Receptor Inhibitor)

Baricitinib (JAK Inhibitor)

Dexamethasone

Convalescent Plasma

Antibiotic Stewardship

📋Treatment Algorithm Summary

🛡️Aerosol-Generating Procedures (AGPs) — PPE Requirements

Procedures Classified as AGPs

HFNC — Special Considerations

🏥PPE Standards by Setting

🌬️Negative Pressure Room Requirements

When Negative Pressure is Unavailable

🧤PPE Doffing Sequence — Highest Risk Step

Recommended Doffing Sequence (WHO/CDC)

Key Principles

🔬Variant Transmission Characteristics & HCW Vaccination in GCC

Omicron — Transmission Changes

GCC HCW Vaccination Requirements

🔁Long COVID — Definition & Prevalence

WHO Definition

Prevalence Estimates

📝Symptoms & Mechanisms

Common Symptoms (in frequency order)

Proposed Mechanisms

❤️Post-COVID Cardiac Complications

Myocarditis

Nursing Monitoring

POTS — Postural Orthostatic Tachycardia Syndrome

Nurse Recognition

🏃Rehabilitation Approach

Graded Activity — KEY PRINCIPLE: PACING

Multidisciplinary Rehabilitation

GCC Long COVID Clinics

🌍GCC Pandemic Response Overview

UAE

Saudi Arabia

Qatar

Kuwait

Bahrain

Oman

💉Vaccines Used in GCC — Comparative Efficacy

👩‍⚕️Impact on Nursing Workforce in GCC

Demand Surge

HCW Protection Measures

🕌COVID-19 and Hajj / Umrah